Judge Dismisses AIDS Healthcare Foundation's Antitrust Suit Against Express Scripts
Judge Lanahan dismissed AIDS Healthcare Foundation's antitrust claims against Express Scripts in 2026.
Why it matters: This ruling highlights the legal challenges specialty pharmacies face when opposing major pharmacy benefit managers. Legal teams in healthcare and pharma should watch how contract terms and prior cases impact antitrust litigation risks.
- On August 25, 2026, U.S. District Judge Maria A. Lanahan dismissed AIDS Healthcare Foundation's (AHF) 2024 antitrust lawsuit against Express Scripts and Accredo Health Group.
- AHF alleged Express Scripts used its market power as a pharmacy benefits manager to impose unfair contract terms, particularly low reimbursement rates from a 2017 Pharmacy Provider Agreement in Louisiana.
- Judge Lanahan ruled the current claims were precluded because they rely on the same facts and seek similar remedies as a prior lawsuit, leading to the dismissal.
- The case underscores the importance of understanding contractual agreements and the doctrine of prior judgment preclusion in antitrust litigation within the healthcare industry.
On August 25, 2026, U.S. District Judge Maria A. Lanahan dismissed the AIDS Healthcare Foundation's (AHF) antitrust claims against Express Scripts and its subsidiary Accredo Health Group. The lawsuit, originally filed in 2024, accused Express Scripts of leveraging its role as a pharmacy benefit manager (PBM) to monopolize specialty pharmacy services in Louisiana.
The litigation focused on the 2017 Pharmacy Provider Agreement, which AHF claimed contained "arbitrary and capricious contract terms," including low reimbursement rates that hindered competition among specialty pharmacies in the state. Judge Lanahan noted that the case "turns on one central allegation" involving these contract terms.
However, Judge Lanahan dismissed the case because the claims were precluded by a prior court judgment. Both the current and earlier lawsuits were based on the same underlying facts and circumstances concerning the 2017 agreement, and sought similar remedies. As a result, the court ruled that the antitrust claims could not proceed.
This ruling highlights the complexities specialty pharmacies face when challenging established contracts with dominant PBMs. It also underscores the impact of legal doctrines like claim preclusion, which bars relitigation of the same disputes, potentially shaping future antitrust strategies in healthcare.
By the numbers:
- August 25, 2026 — date of the antitrust claim dismissal
- 2024 — year AHF filed the antitrust lawsuit
- 2017 — year of the Pharmacy Provider Agreement central to the disputes